Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 9;18(3):2694–2703. doi: 10.3892/ol.2019.10589

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Li et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 1. — Rapa combined with doxorubicin decreases cell proliferation in K562 cells. Doxorubicin treatment with various concentrationsfrom 0.03125–4 µM for (A) 24, (B) 48 and (C) 72 h. The percentage of cells viability was determined by Cell Counting Kit-8 assay. Data were presented as the mean ± SD of triplicates. *P<0.05 vs. the solvent control group. (D) Rapa combined with doxorubicin decreased the cell viability of K562 cells. K562 cells were treated with doxorubicin (0.125, 0.25, 0.5 and 1 µM) and Rapa (10, 20 and 40 nM) for 24 h. Control value was taken as 100%, and *P<0.05 vs. the matched single-drug group. Data were presented as the mean ± SD of triplicates. (E) The CI values were analyzed using the Chou-Talalay method, and the fraction affected (a growth inhibition rates of 25%) is higher than 0.25, CI<1 indicates a synergistic effect. It suggested that Rapa enhanced the anti-proliferative effects of doxorubicin in K562 cells. Rapa, rapamycin; SD, standard deviation.